cobolimab | GSK announces positive headline results from PERLA, the ph

Keyword	CPC	PCC	Volume	Score	Length of keyword
cobolimab	1.41	1	159	78	9

Keyword	CPC	PCC	Volume	Score
cobolimab	0.67	0.6	9765	33
cobolimab gsk	1.62	1	8626	6
cobolimab hcc	0.93	0.1	5701	89
cobolimab costar	0.31	0.9	8881	85
cobolimab fda approval	1.06	0.8	3435	2
cobolimab moa	0.97	0.2	2934	11
cobolimab mechanism of action	1.01	0.4	2765	18
cobolimab tesaro	0.36	1	8573	37
cobolimab gsk4069889	0.69	0.5	1134	91
cobolimab liver cancer	0.6	0.1	9569	2
cobolimab tim-3	1.51	0.4	5334	17
cobolimab nsclc	1.75	0.3	6184	25

Search Results related to cobolimab on Search Engine

GSK announces positive headline results from PERLA, the phase II tri…
gsk.com

https://www.gsk.com/en-gb/media/press-releases/gsk-announces-positive-headline-results-from-perla-the-phase-ii-trial-of-jemperli-dostarlimab-plus-chemotherapy-in-patients-with-metastatic-non-squamous-non-small-cell-lung-cancer/

WEBOct 5, 2022 · PERLA is the largest global head-to-head trial of PD-1 inhibitors in this population. COSTAR, the phase II/III trial combining dostarlimab with …

DA: 90 PA: 80 MOZ Rank: 53

Phase II study of cobolimab in combination with dostarlimab for t…
ascopubs.org

https://ascopubs.org/doi/10.1200/JCO.2023.41.4_suppl.580

WEBJan 24, 2023 · Conclusions: Interim results indicate that the combination of cobolimab and dostarlimab has acceptable safety with encouraging …

DA: 71 PA: 64 MOZ Rank: 21

Phase 1 trial of TIM-3 inhibitor cobolimab monotherapy and in
ascopubs.org

https://ascopubs.org/doi/10.1200/JCO.2022.40.16_suppl.2504

WEBAMBER (NCT02817633) is evaluating cobolimab (TSR-022/GSK4069889)... Phase 1 trial of TIM-3 inhibitor cobolimab monotherapy and in combination with …

DA: 71 PA: 100 MOZ Rank: 80

TIM-3 Inhibitor Cobolimab Is Well-Tolerated, Shows Preliminary Effic…
ascopubs.org

https://dailynews.ascopubs.org/do/tim-3-inhibitor-cobolimab-well-tolerated-shows-preliminary-efficacy-combination

WEBJune 7, 2022. Author Bios. Disclosures. Dr. Gerald S. Falchook. Key Points: The anti–TIM-3 antibody cobolimab had low rates of serious adverse events alone …

DA: 52 PA: 49 MOZ Rank: 74

Cobolimab/Dostarlimab Combination Shows Initial Efficac…
onclive.com

https://www.onclive.com/view/cobolimab-dostarlimab-combination-shows-initial-efficacy-and-safety-signals-in-advanced-nsclc

WEBJan 10, 2024 · Cobolimab/Dostarlimab Combination Shows Initial Efficacy and Safety Signals in Advanced NSCLC. January 10, 2024. Ryan Scott. News. …

DA: 43 PA: 11 MOZ Rank: 46